1International Conference on Harmonisation.Guidance E9:Statistical principles for clinical trials[J/OL].http://www.emea.europa.eu/pdfs/human/ich/036396en.pdf,1998-03-01.
2International Conference on Harmonisation.Guidance E10:Choice of control group and related issues in clinical trials[J/OL].http:// www.emea.europa.eu/pdfs/human/ich/036496en.pdf,2000-07 -01.
6Jones B,Jarvis P,Lewis JA,et al.Trials to assess equivalence:the importance of rigorous methods[J].Br Med J,1996 ;313:36-39.
7Campbell MJ,Julious SA,Altman DG.Estimating sample sizes for binary,ordered categorical,and continuous outcomes in two group comparisons[J].Br Med J,1995 ;311:1145-1148.
8EMEA CPMP:Points to consider on switching between superiority and non-inferiority[J/OL].Http://www.Emea.Europa.Eu/pdfs/human/ewp/048299en.Pdf,2000-07-01.
2Guidance for Industry - Statistical Approaches to Establishing Bioequivalence U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) January 2001 http://www.fda.gov/cder/guidance/index/htm.
3Phillips KF. Power of the two one-sided tests procedure in bioequivalence [J]. J Pharmacokinet Biopharm, 1990; 18(2): 137-144.
4Chapter 56: The Power Procedure (Experimental) :3171～3242 http:// www. support. sas. com/ rnd / app / papers / power.pdf.
5HwangK.Superiority, noninferiority and equivalence trials[A]..新药临床研究生物统计学国际学术研讨会[C].北京,2003,01..
